Description: NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Home Page: www.neubasetherapeutics.com
350 Technology Drive
Pittsburgh,
PA
15219
United States
Phone:
646 450 1790
Officers
| Name | Title |
|---|---|
| Dr. Dietrich A. Stephan Ph.D. | Founder, CEO & Director |
| Mr. Todd P. Branning | CFO & Sec. |
| Dr. Curt Bradshaw Ph.D. | Chief Scientific Officer |
| Mr. Alan Scrivner J.D. | Gen. Counsel |
| Ms. Shannon McCarthy | Chief People Officer |
| Dr. Robert J. Zamboni Ph.D. | Chief of Preclinical Devel. & Member of Scientific Advisory Board |
| Dr. Ron Sarkar M.B.A., Ph.D. | Sr. VP of Corp. Strategy & Bus. Devel. |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2022 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | September |
| Full Time Employees: | 37 |